Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Receives Average Rating of “Hold” from Brokerages

Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) have received an average recommendation of “Hold” from the ten research firms that are covering the stock, Marketbeat.com reports. Seven analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $24.17.

A number of brokerages have commented on DCPH. JMP Securities restated a “market perform” rating on shares of Deciphera Pharmaceuticals in a research report on Tuesday, April 30th. Leerink Partnrs cut Deciphera Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Monday, April 29th. Jefferies Financial Group reiterated a “hold” rating and set a $25.60 target price (down previously from $26.00) on shares of Deciphera Pharmaceuticals in a research report on Monday, April 29th. Guggenheim reiterated a “neutral” rating on shares of Deciphera Pharmaceuticals in a research report on Tuesday, April 30th. Finally, JPMorgan Chase & Co. increased their target price on Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the stock a “neutral” rating in a research report on Wednesday, March 20th.

Institutional Investors Weigh In On Deciphera Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Frazier Life Sciences Management L.P. raised its position in Deciphera Pharmaceuticals by 176.2% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 1,021,800 shares of the company’s stock valued at $16,482,000 after purchasing an additional 651,800 shares in the last quarter. Armistice Capital LLC raised its position in Deciphera Pharmaceuticals by 12.7% during the 4th quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock valued at $83,876,000 after purchasing an additional 588,000 shares in the last quarter. Redmile Group LLC raised its position in Deciphera Pharmaceuticals by 10.3% during the 1st quarter. Redmile Group LLC now owns 5,296,643 shares of the company’s stock valued at $83,316,000 after purchasing an additional 495,103 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Deciphera Pharmaceuticals by 14.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,307,475 shares of the company’s stock valued at $37,220,000 after acquiring an additional 290,968 shares during the period. Finally, Essex Investment Management Co. LLC purchased a new position in shares of Deciphera Pharmaceuticals in the 1st quarter valued at $4,540,000. 70.96% of the stock is owned by institutional investors.

Deciphera Pharmaceuticals Price Performance

Shares of DCPH opened at $25.59 on Friday. The business has a 50-day simple moving average of $25.53 and a two-hundred day simple moving average of $19.23. The stock has a market cap of $2.21 billion, a price-to-earnings ratio of -11.58 and a beta of 0.19. Deciphera Pharmaceuticals has a 52 week low of $9.90 and a 52 week high of $25.61.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last issued its quarterly earnings results on Friday, May 10th. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.03. The business had revenue of $45.00 million during the quarter, compared to analysts’ expectations of $45.99 million. Deciphera Pharmaceuticals had a negative return on equity of 52.42% and a negative net margin of 108.86%. On average, equities analysts anticipate that Deciphera Pharmaceuticals will post -2.15 earnings per share for the current fiscal year.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.